MA38620B1 - Compound (e) -3- (4 - ((3r) -3-methyl-2-propyl-2,3,4,9-tetrahydro-1H-pyrido (3,4-b) indol-1-yl) phenyl ) acrylic acid for the treatment or prevention of breast cancer - Google Patents

Compound (e) -3- (4 - ((3r) -3-methyl-2-propyl-2,3,4,9-tetrahydro-1H-pyrido (3,4-b) indol-1-yl) phenyl ) acrylic acid for the treatment or prevention of breast cancer

Info

Publication number
MA38620B1
MA38620B1 MA38620A MA38620A MA38620B1 MA 38620 B1 MA38620 B1 MA 38620B1 MA 38620 A MA38620 A MA 38620A MA 38620 A MA38620 A MA 38620A MA 38620 B1 MA38620 B1 MA 38620B1
Authority
MA
Morocco
Prior art keywords
treatment
pyrido
indol
tetrahydro
propyl
Prior art date
Application number
MA38620A
Other languages
French (fr)
Other versions
MA38620A1 (en
Inventor
Nadim Akhtar
Robert Bradbury
David Buttar
Gordon Currie
Savi Christopher De
Craig Donald
Richard Norman
Matthew Osborne
Alfred Rabow
Heather Redfearn
Helen Williams
Neda Yavari
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority claimed from PCT/GB2014/051607 external-priority patent/WO2014191726A1/en
Publication of MA38620A1 publication Critical patent/MA38620A1/en
Publication of MA38620B1 publication Critical patent/MA38620B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (i) ou leurs sels pharmaceutiquement acceptables, dans laquelle r1 à r5 ont l'une quelconque des significations définies ici dans la description, des procédés pour les préparer, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de troubles de la prolifération cellulaire.The invention relates to compounds of formula (i) or their pharmaceutically acceptable salts, wherein r1 to r5 have any of the meanings defined herein in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of disorders of cell proliferation.

MA38620A 2013-05-28 2014-05-27 Compound (e) -3- (4 - ((3r) -3-methyl-2-propyl-2,3,4,9-tetrahydro-1H-pyrido (3,4-b) indol-1-yl) phenyl ) acrylic acid for the treatment or prevention of breast cancer MA38620B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827951P 2013-05-28 2013-05-28
PCT/GB2014/051607 WO2014191726A1 (en) 2013-05-28 2014-05-27 Chemical compounds

Publications (2)

Publication Number Publication Date
MA38620A1 MA38620A1 (en) 2018-03-30
MA38620B1 true MA38620B1 (en) 2018-09-28

Family

ID=56120482

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38620A MA38620B1 (en) 2013-05-28 2014-05-27 Compound (e) -3- (4 - ((3r) -3-methyl-2-propyl-2,3,4,9-tetrahydro-1H-pyrido (3,4-b) indol-1-yl) phenyl ) acrylic acid for the treatment or prevention of breast cancer

Country Status (2)

Country Link
AR (1) AR096447A1 (en)
MA (1) MA38620B1 (en)

Also Published As

Publication number Publication date
AR096447A1 (en) 2015-12-30
MA38620A1 (en) 2018-03-30

Similar Documents

Publication Publication Date Title
MA38175B1 (en) Lactams fused to an aryl and heteroaryl
MA41134B1 (en) Substituted compounds of 5-amino-6h-thiazolo [4,5-d] pyrimidin-2,7-dione for the treatment and prophylaxis of viral infections
MA40225A (en) SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
MA38138A1 (en) New derivatives of quinolone
MA40111B1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
JP2016522835A5 (en)
TN2016000188A1 (en) 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS
MA46038A (en) SULFONIMIDOYLPURINONE COMPOUNDS SUBSTITUTED IN POSITION 7 FOR THE TREATMENT AND PROPHYLAXIS OF VIRAL INFECTION
MA38227A1 (en) Novel bicyclic compounds and their use as antibacterial agents and inhibitors of? -Lactamase
TN2009000450A1 (en) PYRIDINE DERIVATIVES
MA39211B1 (en) Tricyclic compounds as anti-cancer agents
MA35036B1 (en) COMPOUNDS BIS (FLUOROALKYL) -1,4-BENZODIAZEPINONE
TN2015000547A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR USE AS LIGANDS OF DOPAMINE D1
TN2015000347A1 (en) AZABENZIMIDAZOLES AS INHIBITORS OF PDE4 ISOENZYMES FOR THE TREATMENT OF CNS DISORDERS AND OTHER DISORDERS
MA37142A3 (en) Derivatives of dihydro-benzo-oxazine and dihydro-pyrido-oxazine
MA34234B1 (en) PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
MA33533B1 (en) Pharmaceutical formulations for the treatment of cancer and other diseases or disorders
MA35342B1 (en) Piperidinyl compounds useful as inhibitors of tankyrase
MA38079A1 (en) Compounds of 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine for use in the treatment of diabetes and its associated disorders
MA38315A1 (en) Heterocycle-substituted tetracyclic compounds and methods for their use in the treatment of viral diseases
MA35932B1 (en) Pyrazolopyrimidinyl inhibitors of the ubiquitin activating enzyme
MA39165A1 (en) Benzimidazole-proline derivatives for their use in the treatment of crepuscular state syndrome
MA43052B1 (en) Human Plasma Kallikrein Inhibitors
MA39186A1 (en) Derivatives of [1,2,4] triazolo [1,5-a] pyrimidine used as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
JP2014532063A5 (en)